Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RAIN THERAPEUTICS INC.

(RAIN)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
7.520 USD   -0.40%
11/23Insider Buy: Rain Therapeutics
MT
11/23Citigroup Adjusts Price Target on Rain Therapeutics to $29 From $30, Maintains Buy Rating
MT
11/23Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Rain Therapeutics to Present at Upcoming Investor Conferences

12/21/2021 | 08:01am EST

NEWARK, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview at the JP Morgan Chase 40th Annual Healthcare Conference and at the H.C. Wainwright Bioconnect Conference, both conferences being held virtually January 10-13, 2022.

Additional details can be found below:

Conference: JP Morgan Chase 40th Annual Healthcare Conference
Date and Time: Thursday, January 13, 2022 at 11:15 a.m. ET
Location: Webcast Link or at the company’s website (click here)

Conference: H.C. Wainwright Bioconnect Conference
Date and Time: Prerecorded presentation will be available beginning Monday, January 10, 2022 at 7:00 a.m. ET
Location: Webcast Link or at the company’s website (click here)

Replay of the corporate overview presentation will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com


All news about RAIN THERAPEUTICS INC.
11/23Insider Buy: Rain Therapeutics
MT
11/23Citigroup Adjusts Price Target on Rain Therapeutics to $29 From $30, Maintains Buy Rati..
MT
11/23Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer..
AQ
11/18Rain Therapeutics to Participate in Piper Sandler's 34th Annual Healthcare Conference
AQ
11/17Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Soci..
AQ
11/14Insider Buy: Rain Therapeutics
MT
11/14Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Vir..
AQ
11/14Rain Therapeutics Inc. : Results of Operations and Financial Condition (form 8-K)
AQ
11/10Transcript : Rain Therapeutics Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
More news
Analyst Recommendations on RAIN THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -71,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,09x
Yield 2022 -
Capitalization 264 M 264 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 44
Free-Float 56,1%
Chart RAIN THERAPEUTICS INC.
Duration : Period :
Rain Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RAIN THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 7,52 $
Average target price 18,17 $
Spread / Average Target 142%
EPS Revisions
Managers and Directors
Avanish Vellanki Chairman & Chief Executive Officer
Robert Doebele President & Chief Scientific Officer
Nelson D. Cabatuan Senior Vice President-Finance & Administration
Lucio Tozzi Senior Vice President-Clinical Operations
Richard Paul Bryce Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RAIN THERAPEUTICS INC.-41.61%264
VERTEX PHARMACEUTICALS44.05%81 199
REGENERON PHARMACEUTICALS, INC.17.41%78 615
BIONTECH SE-36.54%39 760
WUXI APPTEC CO., LTD.-34.05%31 776
GENMAB A/S20.91%28 866